Calcimedica announces publication in the american journal of nephrology discussing design and rationale of phase 2 kourage trial of auxora™ in aki with respiratory failure

Publication includes previously announced preclinical data of auxora™ in acute kidney injury (aki) models as well as a post-hoc analysis of patients in the phase 2 cardea trial of auxora in severe covid-19 pneumonia who had aki with respiratory failure at enrollment la jolla, calif. , june 25, 2025 /prnewswire/ -- calcimedica inc. ("calcimedica" or the "company") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced a publication in the american journal of nephrology (ajn) highlighting the design and rationale of the company's phase 2 kourage trial of lead candidate auxora™ in acute kidney injury (aki) with respiratory failure.
CALC Ratings Summary
CALC Quant Ranking